Enta currently is an hard stock to value at this point. You almost have to run some average yearly rate rather than the Q to Q numbers. Probably somewhere in the high 14% to 15% percent would work.
The real disappointment probably was Abbvie's slow down in growth coupled with evidence that Gilead is stepping up to the plate to garner market share.
All given, ENTA could be in a range considered fair until more details unfold.
News 
Market Data 
Discover 
